9 Apr 2025 • Researchers developed and validated a predictive nomogram to identify chronic hepatitis B (CHB) patients at heightened risk for myelosuppression following peginterferon (Peg-IFN) therapy—a common but serious side effect.

Among the patients, four independent risk factors were identified: lower body mass index (BMI), white blood cell (WBC) count, and globulin (GLB) levels, along with elevated serum creatinine (SCR).

The nomogram incorporating these factors showed strong predictive accuracy, with AUCs of 0.824, 0.812, and 0.870 across training, test, and external validation cohorts, respectively.

Source: Taylor & Francis | Read Full Story